UCB looks to new approvals to push past patent losses

27 July 2023
ucb_large

Belgium’s largest pharma company UCB (Euronext: UCB) has posted a downbeat set of financials for the first half of 2023, with revenues falling 11% to 2.6 billion euros ($2.9 billion).

Despite the drop, with net sales falling 12% to 2.4 billion euros, the company confirmed its financial guidance for the year, with expected revenues of between 5.15 billion euros and 5.35 billion euros.

The company is weathering the impact of encroaching generic competition, with the period of exclusivity for seizure meds Keppra (levetiracetam) and Vimpat (lacosamide) coming to an end.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical